Gastroenterology Research and Practice · 2015 · 29 citations · 20 references
MedicineOncologyPathologyGastrointestinal OncologyMolecular OncologyNeoplasiaCancer BiomarkersCancer Cell SignalingCancer Molecular PathologyGastric CancerHedgehog SignalingMolecular Tumor ProfilingBiomarkers Of Gastric CancerCd44 ExpressionDisease Prognostic BiomarkersDisease-free Survival AnalysisPredictive BiomarkersPrognostic BiomarkersRadical ResectionTnm Staging System
Aim. CD44 and Sonic Hedgehog (Shh) signaling are important for gastric cancer (GC). However, the clinical impact, survival, and recurrence outcome of CD44, Shh, and Gli1 expressions in GC patients following radical resection have not been elucidated. Patients and Methods. CD44, Shh, and Gli1 protein levels were quantified by immunohistochemistry (IHC). The association between CD44, Shh, and Gli1 expression and clinicopathological features or prognosis of GC patients was determined. The biomarker risk score was calculated by the IHC staining score of CD44, Shh, and Gli1 protein. Results. The IHC positive staining of CD44, Shh, and Gli1 proteins was correlated with larger tumour size, worse gross type and histological type, and advanced TNM stage, which also predicted shorter overall survival (OS) and disease-free survival (DFS) after radical resection. Multivariate analysis indicated the Gli1 protein and Gli1, CD44 proteins were predictive biomarkers for OS and DFS, respectively. If biomarker risk score was taken into analysis, it was the independent prognostic factor for OS and DFS. Conclusions. CD44 and Shh signaling are important biomarkers for tumour aggressiveness, survival, and recurrence in GC.
20
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44
Shigeo Takaishi, Tomoyuki Okumura, Shuiping Tu et al. · Stem Cells · 2009 · 1K citations
Medicine, Cell Biology, Oncology +16
Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Adam D. Steg, Kerri S. Bevis, Ashwini A. Katre et al. · Clinical Cancer Research · 2011 · 368 citations · Full text
Medicine, Cancer Biology, Oncology +17